Epigral Q1FY26 net profit drops 38% to ₹99.18 crore as revenue rises 16%
AI Market Summary
Epigral's Q1 FY26 results show revenue up 16% but net profit down 38% YoY as raw material costs rose sharply and last year's one-off deferred tax credit did not recur. EBITDA increased in absolute terms, yet margin compressed, highlighting cost pressure despite growth. The board approved unaudited results with a limited review, and management will address drivers on the earnings call, shaping near-term stock-level positioning.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.84%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Epigral reported Q1FY26 revenue from operations of ₹705.36 crore, up 16% year on year, but standalone net profit fell 38% to ₹99.18 crore. The company attributed the decline to a jump in material costs and the absence of a large one-time deferred tax benefit booked in the year-ago quarter. EBITDA rose to ₹1.8B, while the EBITDA margin narrowed to 25.39% from 27%. The unaudited results were approved by the board and received a limited review from the statutory auditor.
